9 recruiting, 2 completed, 1 active not recruiting, 1 not yet recruiting. 6 Phase 2, 4 Phase 1, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 4, Completed 1, Not yet recruiting 1 |
| Phase 1 | 4 | Recruiting 3, Active not recruiting 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Hormone Receptor Positive HER-2 Negative Breast Cancer: new trials by email Literature Review of Hormone Receptor Positive HER-2 Negative Breast Cancer trials Research Report on Hormone Receptor Positive HER-2 Negative Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC RYZ211/212 - Metastatic Urothelial Carcinoma, Breast Cancer | Early Phase 1 | Recruiting | RayzeBio, Inc. | 40 | 2026-06-15 | 2026-10-13 |
| A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer HLX43 - Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 2 | Not yet recruiting | Shanghai Henlius Biotech | 60 | 2026-04-01 | 2026-03-10 |
| Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Olaparib + Elacestrant, Olaparib - Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer | Phase 2 | Recruiting | GBG Forschungs GmbH | 176 | 2024-12-13 | 2025-12-01 |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer Alisertib, Endocrine therapy - Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Puma Biotechnology, Inc. | 225 | 2024-11-19 | 2026-10-01 |
| A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors BG-68501, Fulvestrant, BGB-43395 - Breast Cancer, Small Cell Lung Cancer | Phase 1 | Active not recruiting | BeiGene | 103 | 2024-03-11 | 2026-10-20 |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors BGB-43395, Fulvestrant, Letrozole - Advanced Solid Tumor, Advanced Breast Cancer | Phase 1 | Recruiting | BeOne Medicines | 433 | 2023-12-01 | 2026-10-15 |
| TCb vs EC-T in High Risk ER+/HER2- Breast Cancer Docetaxel, Carboplatin, Epirubicin - Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 3 | Recruiting | Fudan University | 1736 | 2023-06-01 | 2026-09-28 |
| Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study Palbociclib, Ribociclib, Abemaciclib - Breast Adenocarcinoma, Breast Cancer Stage IV | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 3500 | 2023-05-01 | 2025-02-03 | |
| Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer Hormone Receptor Positive HER-2 Negative Breast Cancer | Recruiting | University Hospital Tuebingen | 504 | 2023-04-25 | 2026-02-10 | |
| VS-6766+Abema+Fulv in Met HR+/HER- BC VS-6766, Abemaciclib, Fulvestrant - Breast Cancer, Hormone Receptor-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Adrienne G. Waks | 63 | 2023-02-23 | 2026-04-30 |
| Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer EP0062, Elacestrant, Everolimus - Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Ellipses Pharma | 95 | 2023-01-11 | 2026-06-22 |
| A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib Hormone Receptor Positive HER-2 Negative Breast Cancer | Completed | Novartis | 435 | 2021-06-11 | 2024-11-26 | |
| Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer Palbociclib + Letrozole or Fulvestrant - Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 2 / Phase 3 | Completed | Georgetown University | 35 | 2016-09-01 | 2021-09-28 |
Breast Neoplasms (9) · Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2) · Breast Diseases (1) · Breast Neoplasms, Male (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms (9) · Neoplasms by Site (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Breast Diseases (8) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2)
Fulvestrant (5) · abemaciclib (3) · elacestrant (3) · Letrozole (2) · palbociclib (2) · Carboplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Epirubicin (1) · Everolimus (1) · MLN 8237 (1) · exemestane (1) · olaparib (1) · ribociclib (1)
Adrienne G. Waks (1) · BeOne Medicines (1) · BeiGene (1) · Ellipses Pharma (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Fudan University (1) · GBG Forschungs GmbH (1) · Georgetown University (1) · Novartis (1) · Puma Biotechnology, Inc. (1) · RayzeBio, Inc. (1) · Shanghai Henlius Biotech (1) · University Hospital Tuebingen (1)
United States (7) · Australia (3) · China (3) · New Zealand (3) · Germany (2) · Moldova (2) · Spain (2) · Brazil (1) · France (1) · Israel (1) · Italy (1) · Japan (1) · Malaysia (1) · Portugal (1) · South Africa (1)
Adrienne G Waks, MD (1) · Claudine Isaacs, MD (1) · Dominik Dannehl, Dr. (1) · Freddy Escorcia (1) · Heying Duan (1) · Sibylle Loibl, MD, PhD (1)
2023 (1)